Skip to main content

Main menu

  • Home
  • Content
    • First Release
    • Current
    • Archives
    • Collections
    • Audiovisual Rheum
    • COVID-19 and Rheumatology
  • Resources
    • Guide for Authors
    • Submit Manuscript
    • Author Payment
    • Reviewers
    • Advertisers
    • Classified Ads
    • Reprints and Translations
    • Permissions
    • Meetings
    • FAQ
    • Policies
  • Subscribers
    • Subscription Information
    • Purchase Subscription
    • Your Account
    • Terms and Conditions
  • About Us
    • About Us
    • Editorial Board
    • Letter from the Editor
    • Duncan A. Gordon Award
    • Privacy/GDPR Policy
    • Accessibility
  • Contact Us
  • JRheum Supplements
  • Services

User menu

  • My Cart
  • Log In

Search

  • Advanced search
The Journal of Rheumatology
  • JRheum Supplements
  • Services
  • My Cart
  • Log In
The Journal of Rheumatology

Advanced Search

  • Home
  • Content
    • First Release
    • Current
    • Archives
    • Collections
    • Audiovisual Rheum
    • COVID-19 and Rheumatology
  • Resources
    • Guide for Authors
    • Submit Manuscript
    • Author Payment
    • Reviewers
    • Advertisers
    • Classified Ads
    • Reprints and Translations
    • Permissions
    • Meetings
    • FAQ
    • Policies
  • Subscribers
    • Subscription Information
    • Purchase Subscription
    • Your Account
    • Terms and Conditions
  • About Us
    • About Us
    • Editorial Board
    • Letter from the Editor
    • Duncan A. Gordon Award
    • Privacy/GDPR Policy
    • Accessibility
  • Contact Us
  • Follow jrheum on Twitter
  • Visit jrheum on Facebook
  • Follow jrheum on LinkedIn
  • Follow jrheum on YouTube
  • Follow jrheum on Instagram
  • Follow jrheum on RSS
Research ArticleArticle

Systemic Sclerosis and the Risk of Tuberculosis

Shuo-Ming Ou, Wen-Chien Fan, Kun-Ta Cho, Chiu-Mei Yeh, Vincent Yi-Fong Su, Man-Hsin Hung, Yu-Sheng Chang, Yi-Jung Lee, Yung-Tai Chen, Pei-Wen Chao, Wu-Chang Yang, Tzeng-Ji Chen, Wei-Shu Wang, Hsuan-Ming Tsao, Li-Fu Chen, Fa-Yauh Lee and Chia-Jen Liu
The Journal of Rheumatology August 2014, 41 (8) 1662-1669; DOI: https://doi.org/10.3899/jrheum.131125
Shuo-Ming Ou
From the Division of Nephrology, the Division of Hematology and Oncology, and the Division of Gastroenterology, Department of Medicine, the Department of Neurology, Neurological Institute, the Department of Chest Medicine, and the Department of Family Medicine, Taipei Veterans General Hospital, Taipei; Division of Chest Medicine, Da-Chien General Hospital, Miaoli; School of Medicine, Institute of Clinical Medicine, Institute of Public Health, and Department of Internal Medicine, National Yang-Ming University; Division of Allergy, Immunology, and Rheumatology, Department of Internal Medicine, Shuang Ho Hospital; Department of Medicine, Taipei City Hospital Heping Fuyou Branch; Department of Anesthesiology, Wan Fang Hospital, Taipei Medical University, Taipei; Department of Emergency Medicine, National Yang-Ming University Hospital, Yilan, Taiwan.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Wen-Chien Fan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Kun-Ta Cho
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Chiu-Mei Yeh
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Vincent Yi-Fong Su
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Man-Hsin Hung
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Yu-Sheng Chang
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Yi-Jung Lee
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Yung-Tai Chen
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Pei-Wen Chao
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Wu-Chang Yang
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Tzeng-Ji Chen
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Wei-Shu Wang
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Hsuan-Ming Tsao
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Li-Fu Chen
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Fa-Yauh Lee
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Chia-Jen Liu
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: chiajenliu@gmail.com
  • Article
  • Figures & Data
  • References
  • Info & Metrics
  • PDF
  • eLetters
PreviousNext
Loading

This article has a correction. Please see:

  • Errata - December 01, 2014

Abstract

Objective. Pulmonary involvement is common in patients with systemic sclerosis (SSc), and this condition causes substantial morbidity and mortality. Disrupted immunity from the disease or associated medication may render such patients subject to tuberculosis (TB) infection. However, the relationship between SSc and TB has not yet been investigated.

Methods. Using the Taiwan National Health Insurance Research Database, 838 patients with SSc diagnosed in Taiwan during 2000–2006 were identified and followed for emergence of TB infection. Incidence rate ratios (IRR) of TB compared to 8380 randomly selected age-, sex-, and comorbidity-matched controls without SSc were calculated. The Cox proportional hazards model was used for multivariate adjustment to identify independent risk factors for TB infection.

Results. The risk of TB infection was higher in the SSc cohort than in controls (IRR 2.81, 95% CI 1.36–5.37; p = 0.004), particularly for pulmonary TB (IRR 2.53, 95% CI 1.08–5.30; p = 0.022). Other independent risk factors for TB infection in patients with SSc were age ≥ 60 years [hazard ratio (HR) 3.52, 95% CI 1.10–11.33; p = 0.035] and pulmonary hypertension (PH; HR 6.06, 95% CI 1.59–23.17; p = 0.008). Mortality did not differ for SSc patients with or without TB.

Conclusion. In this nationwide study, the incidence of TB infection was significantly higher among patients with SSc than in controls without SSc. Special care should be taken in managing patients with SSc who are at high risk for TB, especially those aged ≥ 60 years or who also have PH.

Key Indexing Terms:
  • SYSTEMIC SCLEROSIS
  • PULMONARY HYPERTENSION
  • PULMONARY FIBROSIS
  • TUBERCULOSIS

Systemic sclerosis (SSc) is an autoimmune disorder characterized by small vasculopathy, autoantibody production, and fibrosis of multiple organs (skin, gastrointestinal tract, lung, kidney, and heart)1. Two major pulmonary involvements associated with SSc, pulmonary hypertension (PH) and interstitial lung disease (ILD), can occur either together or independently. Each pulmonary compromise, when present, is currently the leading cause of morbidity and mortality in patients with SSc2,3. The crucial components underlying the pathogenesis of SSc include endothelial dysfunction and dysregulation of fibroblasts, which results in excessive collagen production, and profound abnormalities of the immune system4.

Tuberculosis (TB) remains a major public health problem and is responsible for an estimated 1.7 million global deaths per year5. Patients with SSc may be at risk of TB infection because of defective immunity from SSc or associated immunosuppressant therapy. TB might be acquired from an active infected person or from reactivation of a preexisting quiescent lesion. Pulmonary involvement is common in SSc and usually affects the architecture of both the lung tissue and pulmonary vessels6. Previous studies demonstrated that structurally damaging lung diseases, such as chronic ILD7, chronic obstructive pulmonary disease (COPD)8, bronchiectasis9, or pneumoconiosis10, can impair local host immunity and further increase susceptibility to TB infection. However, although a few case reports have been published11,12, no large-scale study has been conducted on the incidence, risk factors, and mortality rates among patients with SSc who develop TB, to our knowledge. Therefore, we performed a longitudinal nationwide cohort study using the Taiwan National Health Insurance Research Database (NHIRD) to investigate the relationship between SSc and incident TB infection.

MATERIALS AND METHODS

Data sources

The Taiwanese government began the National Health Insurance (NHI) program in 1995 to provide comprehensive healthcare for all citizens. Enrollment in this program is mandatory, and coverage of the population reached 98.29% in 200613. Comprehensive medical care including outpatient, inpatient, emergency, dental, traditional Chinese medicine services, and prescription drugs are provided by the NHI program. In 1999, the Bureau of National Health Insurance began releasing patient data (e.g., NHI enrollment files, claims data, and a prescription drug registry) in electronic form under the NHIRD project for research.

For catastrophic illnesses such as SSc, the government registered the confirmed subjects, after strict verification14, in the special category “Catastrophic Illness” in NHIRD. We obtained data from this dataset that included all claims information for patients with catastrophic illnesses. The application of a catastrophic illness certificate for SSc requires a comprehensive review of medical records, examination reports, and the results of imaging studies by physicians. After successful certification, patients with SSc can be exempted from related medical expenses. Our study was approved by the Institutional Review Board of Taipei Veterans General Hospital (201204022BC).

Study population

We used discharge codes (International Classification of Diseases, 9th revision, and clinical modification ICD-9-CM) in the Registry of Catastrophic Illness. We identified 937 patients who were diagnosed with SSc between January 1, 2000, and December 31, 2006. We defined newly diagnosed TB as a compatible ICD-9-CM code (010–018) plus a prescription for at least 2 anti-TB medications for more than 28 days15,16. We further validated our diagnosis and reclassified the patients as non-TB cases if their initial TB-related ICD-9 codes (010–018) in the NHI reimbursement database were changed to other ICD-9 codes during the followup period, including non-TB mycobacterial infection (ICD-9 code 031), lung cancer (ICD-9 code 162), or positive tuberculin skin test (ICD-9 code 795.5), with discontinuation of anti-TB medications17,18. To assess the reliability of our findings, we conducted a secondary analysis using a definition of TB diagnosis that required the prescription for at least 3 anti-TB medications.

Patients were excluded who were under 20 years of age, had antecedent TB, were followed for less than 30 days, and/or developed TB within 30 days of diagnosis. A total of 838 patients with SSc were included. We also collected information on comorbidities, including diabetes mellitus, hypertension, COPD, chronic kidney disease, cirrhosis, malignancies, and substance abuse. We also analyzed sociodemographic characteristics, such as age, sex, income (NT < $20,000, NT $20,000–39,999, and NT ≥ $40,000), and level of urbanization (level 1, level 2, and level 3) in our analysis19. Urbanization levels are divided according to the Taiwan National Health Research Institute publications. Level 1 designates the most urbanized areas and level 3 designates the least urbanized areas. Medications, including corticosteroids and immunosuppressants, were also retrieved and converted to defined daily dose (DDD), a unit recommended by the World Health Organization. DDD is the assumed average maintenance dose per day of a drug consumed for its main indication in adults and is commonly used for research comparing the use of immunosuppressant agents between international settings20,21. Using the concept of DDD, we could compare any immunosuppressant drugs based on the same standard: (total amount of drug)/(amount of drug in a DDD) = number of DDD. Cumulative DDD (cDDD), which indicates exposed duration, was calculated as the sum of dispensed DDD of any immunosuppressant agent. This calculation allowed us to compare use with the risk of subsequent TB. The cDDD of an immunosuppressant agent within 1 year before TB diagnosis was categorized into 2 groups (< 28 and ≥ 28 cDDD). Drugs used for < 28 cDDD were defined as non-used20.

Control cohort

Subjects without SSc were used as a matched cohort and were randomly selected from 1 million NHI beneficiaries out of a population of 21.4 million enrollees throughout Taiwan in 2000. Because SSc is a relatively rare disorder and the incidence of TB in patients with SSc is even lower, we matched each patient with SSc with 10 non-SSc subjects by age, sex, and presence of comorbidities on the same index date of diagnosis. The same exclusion criteria were applied to the control cohort as to patients with SSc. A total of 8380 people served as the matched control cohort.

Major outcome measured

The 2 cohorts, SSc cohort and matched cohort, were followed for the emergence of TB infection (ICD-9-CM code 010–018). If no TB occurred, subjects were followed to death, or the end of the study period (2006). Because TB is endemic in Taiwan, the Taiwan Centers for Disease Control (CDC) has declared TB as a mandatory notifiable disease22. By law, physicians diagnosing incident TB cases or prescribing anti-TB drugs must report cases to the Taiwan CDC within 1 week, allowing all newly-diagnosed TB cases to be identified.

Statistical analyses

Extraction and computation of data were done using the Perl programming language (version 5.12.2). Microsoft SQL Server 2005 (Microsoft Corporation) was used for data linkage, processing, and sampling. All statistical analyses were done using IBM SPSS statistical software (version 20.0, IBM-SPSS). Data are expressed as means ± SD or medians (interquartile ranges) when appropriate. A chi-square test or Fisher’s exact test was used for categorical variables, and the Mann-Whitney U test was used for parametric and nonparametric variables. Incidence rates (per 10,000 person-yrs) and incidence rate ratios (IRR) were analyzed. The Kaplan-Meier method was used for estimation of cumulative incidence. For multivariate adjustment, the Cox proportional hazards model was used to compute hazard ratios (HR) as well as 95% CI. A p < 0.05 was considered significant.

RESULTS

Patient characteristics

Figure 1 shows the study entry flow chart. A total of 838 patients were included after excluding patients who were younger than age 20 when diagnosed (n = 40), had antecedent TB (n = 44), were followed for fewer than 30 days (n = 11), or were diagnosed with TB within 30 days after SSc diagnosis (n = 4). The study population had a median age of 49 years (range 20–87 yrs), and was 76.3% women. The baseline characteristics of patients with and without SSc are in Table 1. Age, sex, and underlying comorbidities were matched between the study and control groups.

Figure 1.
  • Download figure
  • Open in new tab
  • Download powerpoint
Figure 1.

Patient selection flow chart.

View this table:
  • View inline
  • View popup
Table 1.

Baseline characteristics of patients with systemic sclerosis (SSc) and the matched cohort.

Comparison of incidence rates of TB between SSc cohort and controls cohort

Kaplan-Meier analysis showed that the cumulative incidence of TB was significantly higher in the SSc cohort than in the control cohort (log-rank test; p = 0.001; Figure 2). As shown in Table 2, among the 9218 patients (838 SSc cases and 8380 matched controls) in our study during a 7-year period, 60 (0.7%) cases of newly diagnosed TB were identified, including 12 with SSc and 48 in the matched controls. The incidence rate of TB in the SSc cohort was higher than in the matched cohort (41.4 vs 14.7 per 10,000 person-yrs, p = 0.004). The SSc cohort had a 2.81-fold greater risk of TB infection than the matched cohort (IRR 2.81, 95% CI 1.36–5.37; p = 0.004). If TB cases were further classified as pulmonary versus extrapulmonary TB, the SSc cohort still had an increased risk of developing pulmonary TB (IRR 2.53, 95% CI 1.08–5.30; p = 0.022) compared to the matched cohort. Although not significant, the SSc cohort also had an increased risk of developing extrapulmonary TB (IRR 4.22, 95% CI 0.27–17.57; p = 0.064).

Figure 2.
  • Download figure
  • Open in new tab
  • Download powerpoint
Figure 2.

Cumulative incidence of tuberculosis (TB) in patients with systemic sclerosis and the matched cohort.

View this table:
  • View inline
  • View popup
Table 2.

Incidence of pulmonary and extrapulmonary tuberculosis (TB) in patients with systemic sclerosis (SSc) and the matched cohort.

As shown in Table 3, we performed multivariable Cox proportional hazards model analysis and found that SSc itself was an independent risk factor for TB infection (HR 2.99, 95% CI 1.58–5.63; p = 0.001). Other independent risk factors included age ≥ 60 years (HR 2.79, 95% CI 1.66–4.71; p < 0.001) and having COPD (HR 2.19, 95% CI 1.30–3.68; p = 0.003). We further conducted a secondary analysis using a definition of TB diagnosis requiring prescriptions for at least 3 anti-TB medications, which did not significantly alter the results of the primary analysis (Appendix 1).

View this table:
  • View inline
  • View popup
Table 3.

Cox regression of risk factors for tuberculosis (TB).

TB risk factors in patients with SSc

Of 838 patients with SSc, 521 (62.2%) received corticosteroid, 102 (12.2%) received cyclophosphamide (CYC), 10 (1.2%) received cyclosporine, 32 (3.8%) received methotrexate, and 46 (5.5%) received azathioprine. Univariate Cox regression analysis identified 4 risk factors for TB in patients with SSc: age ≥ 60, PH, use of corticosteroids, and use of CYC (Table 4). Multivariate Cox regression hazards analysis indicated that 2 variables were independent risk factors for TB in patients with SSc: age ≥ 60 (HR 3.52, 95% CI 1.10–11.33; p = 0.035) and having PH (HR 6.06, 95% CI 1.59–23.17; p = 0.008). Other factors, including use of corticosteroids or CYC, were not significant in the multivariable analysis. Of the patients with SSc during the study period, 4 of 12 patients (33.3%) with TB died, compared to 119 of 826 patients (14.4%) without TB (p = 0.066).

View this table:
  • View inline
  • View popup
Table 4.

Cox regression of risk factors for tuberculosis (TB) in the systemic sclerosis (SSc) cohort.

DISCUSSION

This is the first study, to our knowledge, to investigate the association between SSc and TB using a nationwide population-based cohort. We compared the cumulative incidence of TB in patients with SSc to the matched cohort. This study had a long followup period and its findings provide several new insights: (1) patients with SSc had a significantly increased risk of developing TB (IRR 2.81) compared to the matched controls during the 7-year study period; (2) SSc itself might be an independent risk factor for TB development; (3) patients with SSc had 2.53 times greater risk of developing pulmonary TB than patients in the matched cohort; and (4) age ≥ 60 years and PH were risk factors for TB in the SSc cohort.

In 1987, Cowie23 reported a 40% incidence of prior TB in black gold miners with SSc. Despite noting a possible association between TB and SSc, the results of that earlier study might be confounded by silica exposure/silicosis. To date, previous studies that have explored the association between SSc and TB are a report of a Japanese-Canadian woman24, 2 Russian cases25,26, and an Indian case series of 13 patients with SSc who developed TB11. However, the findings of the Indian report were limited by a small sample size, a lack of a control group, and a high women-to-men ratio (23:1). Our study found a 2.81-fold higher incidence of TB in patients with SSc (41.4 per 10,000 person-yrs) than in matched controls (14.7 per 10,000 person-yrs). Moreover, our study demonstrated that SSc itself was an independent risk factor for TB infection after adjusting for other confounders.

SSc is an autoimmune disorder characterized by abnormalities of both the cellular and humoral immunity27. SSc patients have reduced numbers of circulating T lymphocytes, and reportedly decreased lymphocyte proliferation28,29. The subpopulation of T lymphocytes regulating cell-mediated immunity is also selectively reduced30. Impaired immunity could predispose patients with SSc to TB infection.

Our study found that compared to controls, patients with SSc were at a greater risk for developing pulmonary TB. The risk for extrapulmonary TB showed a trend toward significance (IRR = 4.22, p = 0.064). Up to 70% to 90% of patients with SSc had pulmonary involvement, which might predispose patients to pulmonary TB31,32. To our knowledge, this is the first study to demonstrate that SSc with pulmonary involvement, especially PH, was an independent risk factor for TB (HR 6.06). PH in SSc can result from fibroblast stimulation by a number of cytokines produced by activated macrophages including transforming growth factor (TGF)-β, tumor necrosis factor (TNF)-α, platelet-derived growth factor, and fibronectin. Fibroblast stimulation also leads to increased vascular endothelial growth factor and thus aberrant neoangiogenesis33. Increased levels of TNF-α and TGF-β are reported to suppress the protective immune response against TB34,35,36. However, work is still needed to elucidate the mechanism of the close relationship between SSc and TB. Further, patients with SSc and ILD had a 3.02 times greater risk for TB, although these results were not significant (p = 0.097). Previous studies found evidence of ILD in 60% to 91% of patients with SSc, as evaluated by high-resolution computed tomography. However, only 26% of the patients were evaluated by physical examination and only 22% by chest radiograph37,38. A high rate of underdiagnosis of ILD in patients with SSc could be the reason the results were not significant.

We observed a trend of higher extrapulmonary involvement in patients with SSc who developed TB than in the matched cohort (IRR 4.22). These data were not significant, possibly because of the limited number of TB subjects (p = 0.064). Our results are similar to previous findings on patients with other autoimmune disorders, systemic lupus erythematous39,40, rheumatoid arthritis treated with biological agents41,42, and inflammatory myositis, all of which can lead to TB with greater extrapulmonary spread43. This is in part due to intrinsic immune dysregulation, permitting the TB bacilli to activate in organs where it is less often successful. The application of systemic corticosteroids and immunosuppressant agents might increase the risk of TB reactivation and dissemination to extrapulmonary sites. A case series by Ahmad, et al11 found an increased incidence of TB among patients with SSc receiving dexamethasone therapy. Although we observed that use of corticosteroids was associated with an elevated HR for TB, the result was not statistically significant in the multivariable model. Perhaps use of corticosteroid is a relatively small TB risk factor in this cohort.

Our study has several limitations. First, the administrative data in the registry database did not contain information about smoking status, physical activity, body mass index, or laboratory and image data. Additionally, data regarding some clinical characteristics (such as the distinction of localized, limited, or diffuse SSc) were not recorded in the NHI database. Therefore, we could not explore the link between these clinical features and TB in patients with SSc. However, this common limitation has been noted in previous registry studies15,44. Besides, we did not use the standard procedure for TB diagnosis (acid-fast stain and culturing). Second, subjects who had antecedent TB were not included in our study. The analyses do not determine whether patients with SSc who developed TB had a recent new infection or reactivation of a remote latent infection. Third, physicians apply for a catastrophic illness certificate of SSc based on whether there is the presence of characteristic cutaneous finding of skin thickening, additional extracutaneous manifestations, capillaroscopic abnormalities, and SSc-related autoantibodies. However, the results of diagnostic tests for SSc were not available in our registry data. Finally, we were unable to evaluate the risk of TB development during childhood or adolescence in patients with SSc because we excluded patients < 20 years old. TB in childhood or adolescence is different from adult TB. Child/adolescent TB often comes from transmission from the community or school and is more likely to be complicated by extrapulmonary involvement45,46.

Patients with SSc had a higher risk for pulmonary TB. Hence, a high index of suspicion and more thorough investigation of suspected TB cases, especially in patients with SSc and PH, could minimize the delay in TB diagnosis and the potential harm to public health in a TB-endemic country.

APPENDIX 1.

View this table:
  • View inline
  • View popup
APPENDIX 1.

Cox regression of risk factors for tuberculosis (TB).

Footnotes

  • Supported by a grant from Taipei Veterans General Hospital (V101D-001-2). The study is based in part on data from the National Health Insurance Research Database provided by the Bureau of National Health Insurance, Department of Health and managed by National Health Research Institutes. The interpretation and conclusions contained herein do not represent those of the Bureau of National Health Insurance, Department of Health, or National Health Research Institutes.

  • Accepted for publication April 7, 2014.

REFERENCES

  1. 1.↵
    1. Gabrielli A,
    2. Avvedimento EV,
    3. Krieg T
    . Scleroderma. N Engl J Med 2009;360:1989–2003.
    OpenUrlCrossRefPubMed
  2. 2.↵
    1. Wells AU,
    2. Steen V,
    3. Valentini G
    . Pulmonary complications: one of the most challenging complications of systemic sclerosis. Rheumatology 2009;48 Suppl 3:iii40–4.
    OpenUrlAbstract/FREE Full Text
  3. 3.↵
    1. Steen VD,
    2. Medsger TA
    . Changes in causes of death in systemic sclerosis, 1972–2002. Ann Rheum Dis 2007;66:940–4.
    OpenUrlAbstract/FREE Full Text
  4. 4.↵
    1. Jimenez SA,
    2. Derk CT
    . Following the molecular pathways toward an understanding of the pathogenesis of systemic sclerosis. Ann Intern Med 2004;140:37–50.
    OpenUrlCrossRefPubMed
  5. 5.↵
    1. World Health Organization
    . Global tuberculosis control: surveillance, planning, financing. 2008. [Internet. Accessed June 10, 2014.] Available from: www.who.int/tb/publications/global_report/2008/en/index.html
  6. 6.↵
    1. Sgonc R,
    2. Wick G
    . Pro- and anti-fibrotic effects of TGF-beta in scleroderma. Rheumatology 2008;47 Suppl 5:v5–7.
    OpenUrlAbstract/FREE Full Text
  7. 7.↵
    1. Shachor Y,
    2. Schindler D,
    3. Siegal A,
    4. Lieberman D,
    5. Mikulski Y,
    6. Bruderman I
    . Increased incidence of pulmonary tuberculosis in chronic interstitial lung disease. Thorax 1989;44:151–3.
    OpenUrlAbstract/FREE Full Text
  8. 8.↵
    1. Inghammar M,
    2. Ekbom A,
    3. Engstrom G,
    4. Ljungberg B,
    5. Romanus V,
    6. Lofdahl CG,
    7. et al.
    COPD and the risk of tuberculosis—a population-based cohort study. PloS One 2010;5:e10138.
    OpenUrlCrossRefPubMed
  9. 9.↵
    1. Jordan TS,
    2. Spencer EM,
    3. Davies P
    . Tuberculosis, bronchiectasis and chronic airflow obstruction. Respirology 2010;15:623–8.
    OpenUrlCrossRefPubMed
  10. 10.↵
    1. Cochrane AL
    . Tuberculosis and coalworkers’ pneumoconiosis. Br J Tuberc Dis Chest 1954;48:274–85.
    OpenUrlCrossRefPubMed
  11. 11.↵
    1. Ahmad QM,
    2. Shah IH,
    3. Nauman Q,
    4. Sameem F,
    5. Sultan J
    . Increased incidence of tuberculosis in patients of systemic sclerosis on dexamethasone pulse therapy: a short communication from Kashmir. Indian J Dermatol 2008;53:24–5.
    OpenUrlCrossRefPubMed
  12. 12.↵
    1. Manz B,
    2. Noack-Wiemers F,
    3. Mittag M,
    4. Haustein UF,
    5. Nenoff P
    . Death due to pulmonary tuberculosis in progressive systemic sclerosis. J Eur Acad Dermatol Venereol 2002;16:647–8.
    OpenUrlCrossRefPubMed
  13. 13.↵
    1. Lin HP,
    2. Deng CY,
    3. Chou P
    . Diagnosis and treatment delay among pulmonary tuberculosis patients identified using the Taiwan reporting enquiry system, 2002–2006. BMC Public Health 2009;9:55.
    OpenUrlCrossRefPubMed
  14. 14.↵
    1. Liu CJ,
    2. Chang YS,
    3. Teng CJ,
    4. Chen TJ,
    5. Ou SM,
    6. Tzeng CH,
    7. et al.
    Risk of extrathymic cancer in patients with myasthenia gravis in Taiwan: a nationwide population-based study. Eur J Neurol 2012;19:746–51.
    OpenUrlCrossRefPubMed
  15. 15.↵
    1. Wu CY,
    2. Hu HY,
    3. Pu CY,
    4. Huang N,
    5. Shen HC,
    6. Li CP,
    7. et al.
    Pulmonary tuberculosis increases the risk of lung cancer: a population-based cohort study. Cancer 2011;117:618–24.
    OpenUrlCrossRefPubMed
  16. 16.↵
    1. Chang YS,
    2. Liu CJ,
    3. Ou SM,
    4. Hu YW,
    5. Chen TJ,
    6. Lee HT,
    7. et al.
    Tuberculosis infection in primary Sjogren’s syndrome: a nationwide population based study. Clin Rheumatol 2014;33:377–83.
    OpenUrlCrossRefPubMed
  17. 17.↵
    1. Lin HH,
    2. Ezzati M,
    3. Chang HY,
    4. Murray M
    . Association between tobacco smoking and active tuberculosis in Taiwan: prospective cohort study. Am J Respir Crit Care Med 2009;180:475–80.
    OpenUrlCrossRefPubMed
  18. 18.↵
    1. Baker MA,
    2. Lin HH,
    3. Chang HY,
    4. Murray MB
    . The risk of tuberculosis disease among persons with diabetes mellitus: a prospective cohort study. Clin Infect Dis 2012;54:818–25.
    OpenUrlAbstract/FREE Full Text
  19. 19.↵
    1. Hou SW,
    2. Lee YK,
    3. Hsu CY,
    4. Lee CC,
    5. Su YC
    . Increased risk of acute pancreatitis in patients with chronic hemodialysis: a 4-year follow-up study. PloS One 2013;8:e71801.
    OpenUrlCrossRefPubMed
  20. 20.↵
    1. Tsan YT,
    2. Lee CH,
    3. Wang JD,
    4. Chen PC
    . Statins and the risk of hepatocellular carcinoma in patients with hepatitis B virus infection. J Clin Oncol 2012;30:623–30.
    OpenUrlAbstract/FREE Full Text
  21. 21.↵
    WHO Collaborating Center for Drugs Statistics Methodology: ATC Index with DDDs 2003. Oslo, Norway, WHO, 2003.
  22. 22.↵
    1. Ou SM,
    2. Liu CJ,
    3. Teng CJ,
    4. Lin YT,
    5. Chang YS,
    6. Chiang SC,
    7. et al.
    Impact of pulmonary and extrapulmonary tuberculosis infection in kidney transplantation: a nationwide population-based study in Taiwan. Transpl Infect Dis 2012;14:502–9.
    OpenUrlCrossRefPubMed
  23. 23.↵
    1. Cowie RL
    . Silica-dust-exposed mine workers with scleroderma (systemic sclerosis). Chest 1987;92:260–2.
    OpenUrlCrossRefPubMed
  24. 24.↵
    1. Roddy J,
    2. Holtby S,
    3. Seigel S
    . Scleroderma concurrent with culture proven tuberculosis in a Japanese Canadian patient. Rheumatol 1996;23:2168–70.
    OpenUrl
  25. 25.↵
    1. Tiukhtin NS,
    2. Berlova ZD
    . [Exudative pleurisy with a tuberculous etiology in a patient with systemic scleroderma]. [Article in Russian] Probl Tuberk 1979;(3):68–70.
  26. 26.↵
    1. Kazak TI,
    2. Teriaeva MV,
    3. Turintsev BB,
    4. Davlinskaia OI
    . [A case of steroid tuberculosis in systemic scleroderma].[Article in Russian] Probl Tuberk 1996;(2):57–8.
  27. 27.↵
    1. Haustein UF,
    2. Anderegg U
    . Pathophysiology of scleroderma: an update. J Eur Acad Dermatol Venereol 1998;11:1–8.
    OpenUrlPubMed
  28. 28.↵
    1. Baron M,
    2. Keystone EC,
    3. Gladman DD,
    4. Lee P,
    5. Poplonski L
    . Lymphocyte subpopulations and reactivity to mitogens in patients with scleroderma. Clin Exp Immunol 1981;46:70–6.
    OpenUrlPubMed
  29. 29.↵
    1. Whiteside TL,
    2. Kumagai Y,
    3. Roumm AD,
    4. Almendinger R,
    5. Rodnan GP
    . Suppressor cell function and T lymphocyte subpopulations in peripheral blood of patients with progressive systemic sclerosis. Arthritis Rheum 1983;26:841–7.
    OpenUrlCrossRefPubMed
  30. 30.↵
    1. Behar SM,
    2. Porcelli SA
    . Mechanisms of autoimmune disease induction. The role of the immune response to microbial pathogens. Arthritis Rheum 1995;38:458–76.
    OpenUrlCrossRefPubMed
  31. 31.↵
    1. Minai OA,
    2. Dweik RA,
    3. Arroliga AC
    . Manifestations of scleroderma pulmonary disease. Clin Chest Med 1998;19:713–31, viii–ix.
    OpenUrlCrossRefPubMed
  32. 32.↵
    1. Gohari Moghadam K,
    2. Gharibdoost F,
    3. Parastandechehr G,
    4. Salehian P
    . Assessments of pulmonary involvement in patients with systemic sclerosis. Arch Iran Med 2011;14:22–6.
    OpenUrlPubMed
  33. 33.↵
    1. Johnson SR,
    2. Granton JT
    . Pulmonary hypertension in systemic sclerosis and systemic lupus erythematosus. Eur Respir Rev 2011;20:277–86.
    OpenUrlAbstract/FREE Full Text
  34. 34.↵
    1. Deveci F,
    2. Akbulut HH,
    3. Turgut T,
    4. Muz MH
    . Changes in serum cytokine levels in active tuberculosis with treatment. Mediators Inflamm 2005;2005:256–62.
    OpenUrlCrossRefPubMed
  35. 35.↵
    1. Boom WH,
    2. Canaday DH,
    3. Fulton SA,
    4. Gehring AJ,
    5. Rojas RE,
    6. Torres M
    . Human immunity to M. tuberculosis: T cell subsets and antigen processing. Tuberculosis 2003;83:98–106.
    OpenUrlCrossRefPubMed
  36. 36.↵
    1. Sharma S,
    2. Bose M
    . Role of cytokines in immune response to pulmonary tuberculosis. Asian Pac J Allergy Immunol 2001;19:213–9.
    OpenUrlPubMed
  37. 37.↵
    1. Steele R,
    2. Hudson M,
    3. Lo E,
    4. Baron M
    . Clinical decision rule to predict the presence of interstitial lung disease in systemic sclerosis. Arthritis Care Res 2012;64:519–24.
    OpenUrlCrossRef
  38. 38.↵
    1. Moore OA,
    2. Goh N,
    3. Corte T,
    4. Rouse H,
    5. Hennessy O,
    6. Thakkar V,
    7. et al.
    Extent of disease on high-resolution computed tomography lung is a predictor of decline and mortality in systemic sclerosis-related interstitial lung disease. Rheumatology 2013;52:155–60.
    OpenUrlAbstract/FREE Full Text
  39. 39.↵
    1. Hou CL,
    2. Tsai YC,
    3. Chen LC,
    4. Huang JL
    . Tuberculosis infection in patients with systemic lupus erythematosus: pulmonary and extra-pulmonary infection compared. Clin Rheumatol 2008;27:557–63.
    OpenUrlCrossRefPubMed
  40. 40.↵
    1. Zhang L,
    2. Wang DX,
    3. Ma L
    . [A clinical study of tuberculosis infection in systemic lupus erythematosus].[Article in Chinese] Zhonghua Nei Ke Za Zhi 2008;47:808–10.
    OpenUrlPubMed
  41. 41.↵
    1. Silva DG,
    2. Silva BD,
    3. Junqueira-Kipnis AP,
    4. Rabahi MF
    . [Tuberculosis in rheumatoid arthritis patients: the difficulty in making the diagnosis of latent infection].[Article in Portuguese] J Bras Pneumol 2010;36:243–51.
    OpenUrlPubMed
  42. 42.↵
    1. Baronnet L,
    2. Barnetche T,
    3. Kahn V,
    4. Lacoin C,
    5. Richez C,
    6. Schaeverbeke T
    . Incidence of tuberculosis in patients with rheumatoid arthritis. A systematic literature review. Joint Bone Spine 2011;78:279–84.
    OpenUrlCrossRefPubMed
  43. 43.↵
    1. Marie I,
    2. Menard JF,
    3. Hachulla E,
    4. Cherin P,
    5. Benveniste O,
    6. Tiev K,
    7. et al.
    Infectious complications in polymyositis and dermatomyositis: a series of 279 patients. Semin Arthritis Rheum 2011;41:48–60.
    OpenUrlCrossRefPubMed
  44. 44.↵
    1. Li SY,
    2. Chen TJ,
    3. Chung KW,
    4. Tsai LW,
    5. Yang WC,
    6. Chen JY,
    7. et al.
    Mycobacterium tuberculosis infection of end-stage renal disease patients in Taiwan: a nationwide longitudinal study. Clin Microbiol Infect 2011;17:1646–52.
    OpenUrlCrossRefPubMed
  45. 45.↵
    1. Nemir RL
    . Perspectives in adolescent tuberculosis: three decades of experience. Pediatrics 1986;78:399–405.
    OpenUrlAbstract/FREE Full Text
  46. 46.↵
    1. Wong KS,
    2. Chiu CH,
    3. Huang YC,
    4. Lin TY
    . Childhood and adolescent tuberculosis in northern Taiwan: an institutional experience during 1994–1999. Acta Paediatr 2001;90:943–7.
    OpenUrlPubMed
PreviousNext
Back to top

In this issue

The Journal of Rheumatology
Vol. 41, Issue 8
1 Aug 2014
  • Table of Contents
  • Table of Contents (PDF)
  • Index by Author
  • Editorial Board (PDF)
Print
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word about The Journal of Rheumatology.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Systemic Sclerosis and the Risk of Tuberculosis
(Your Name) has forwarded a page to you from The Journal of Rheumatology
(Your Name) thought you would like to see this page from the The Journal of Rheumatology web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Systemic Sclerosis and the Risk of Tuberculosis
Shuo-Ming Ou, Wen-Chien Fan, Kun-Ta Cho, Chiu-Mei Yeh, Vincent Yi-Fong Su, Man-Hsin Hung, Yu-Sheng Chang, Yi-Jung Lee, Yung-Tai Chen, Pei-Wen Chao, Wu-Chang Yang, Tzeng-Ji Chen, Wei-Shu Wang, Hsuan-Ming Tsao, Li-Fu Chen, Fa-Yauh Lee, Chia-Jen Liu
The Journal of Rheumatology Aug 2014, 41 (8) 1662-1669; DOI: 10.3899/jrheum.131125

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero

 Request Permissions

Share
Systemic Sclerosis and the Risk of Tuberculosis
Shuo-Ming Ou, Wen-Chien Fan, Kun-Ta Cho, Chiu-Mei Yeh, Vincent Yi-Fong Su, Man-Hsin Hung, Yu-Sheng Chang, Yi-Jung Lee, Yung-Tai Chen, Pei-Wen Chao, Wu-Chang Yang, Tzeng-Ji Chen, Wei-Shu Wang, Hsuan-Ming Tsao, Li-Fu Chen, Fa-Yauh Lee, Chia-Jen Liu
The Journal of Rheumatology Aug 2014, 41 (8) 1662-1669; DOI: 10.3899/jrheum.131125
del.icio.us logo Digg logo Reddit logo Twitter logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One
Bookmark this article

Jump to section

  • Article
    • Abstract
    • MATERIALS AND METHODS
    • RESULTS
    • DISCUSSION
    • APPENDIX 1.
    • Footnotes
    • REFERENCES
  • Figures & Data
  • References
  • Info & Metrics
  • PDF
  • eLetters

Keywords

SYSTEMIC SCLEROSIS
PULMONARY HYPERTENSION
PULMONARY FIBROSIS
TUBERCULOSIS

Related Articles

Cited By...

More in this TOC Section

  • Vasculitis: What Have We Learned in the Last 50 Years?
  • Demographic, Lifestyle, and Serologic Risk Factors for Rheumatoid Arthritis (RA)–associated Bronchiectasis: Role of RA-related Autoantibodies
  • The Association of Illness-related Uncertainty With Mental Health in Systemic Autoimmune Rheumatic Diseases
Show more Article

Similar Articles

Keywords

  • systemic sclerosis
  • PULMONARY HYPERTENSION
  • PULMONARY FIBROSIS
  • tuberculosis

Content

  • First Release
  • Current
  • Archives
  • Collections
  • Audiovisual Rheum
  • COVID-19 and Rheumatology

Resources

  • Guide for Authors
  • Submit Manuscript
  • Author Payment
  • Reviewers
  • Advertisers
  • Classified Ads
  • Reprints and Translations
  • Permissions
  • Meetings
  • FAQ
  • Policies

Subscribers

  • Subscription Information
  • Purchase Subscription
  • Your Account
  • Terms and Conditions

More

  • About Us
  • Contact Us
  • My Alerts
  • My Folders
  • Privacy/GDPR Policy
  • RSS Feeds
The Journal of Rheumatology
The content of this site is intended for health care professionals.
Copyright © 2022 by The Journal of Rheumatology Publishing Co. Ltd.
Print ISSN: 0315-162X; Online ISSN: 1499-2752
Powered by HighWire